Antigen-Specific T-Cell Detection Through TCR Clonotype Sequencing

The patent uses sequence-based profiles (digital copies of T cell receptor information) instead of physical multimer staining. By sequencing TCR nucleic acids and creating clonotype profiles, the method captures the essential detection capability without requiring complex fluorescent conjugates and manual staining procedures, thereby reducing labor and reagent development while maintaining detection precision.

The patent replaces the mechanical/staining-based detection system with a molecular sequencing system. Instead of using fluorescent multimers that require manual staining and microscopy, the method uses high-throughput sequencing to detect T cell clonotypes, substituting physical detection mechanisms with molecular biology techniques that are more scalable and less labor-intensive.

The patent extracts and sequences only the relevant nucleic acid sequences encoding T cell receptors, rather than performing complete functional assays. By focusing solely on the TCR gene sequences and their clonotype patterns, the method achieves accurate T cell enumeration without requiring complex assay components such as cytokine stains, proliferation tritium, or ELISPOT membranes, thereby reducing assay complexity while maintaining enumeration precision.

The patent creates digital copies of T cell receptor sequences and analyzes clonotype frequencies from these sequences. This information-theoretic approach replaces physical assay measurements with computational analysis of sequence data, eliminating the need for complex staining protocols, radioactive materials, and manual scoring procedures while achieving comparable or superior enumeration accuracy.

The patent segments the T cell population into distinct clonotypes based on sequence analysis, allowing parallel processing of multiple patients and samples. Instead of sequentially analyzing each patient's T cells through time-consuming single-cell cloning, the method segments and sequences TCR nucleic acids from bulk samples, enabling simultaneous analysis of multiple patients and dramatically reducing processing time while maintaining isolation precision.

The patent performs preliminary sequencing of TCR nucleic acids before any functional analysis or cloning steps. By obtaining sequence data upfront from bulk T cell samples, the method eliminates the need for subsequent time-consuming single-cell isolation and cloning procedures, allowing rapid identification of antigen-specific clonotypes in each patient without sequential processing delays.

The patent extracts and sequences only the specific nucleic acid regions encoding T cell receptor variable regions, rather than performing whole-genome or total-transcriptome sequencing. This targeted extraction approach reduces the amount of sequencing data that needs to be processed, thereby lowering computational analysis complexity while maintaining cost-effectiveness through high-throughput sequencing of only the relevant genomic regions.

Instead of attempting to analyze all T cell functions and characteristics through complex multi-parameter assays, the patent inverts the approach by focusing solely on the sequence information that defines T cell specificity. By concentrating analysis on TCR nucleic acid sequences rather than attempting comprehensive functional profiling, the method reduces analysis complexity while achieving cost-effective high-throughput screening of antigen-specific T cells.